162 related articles for article (PubMed ID: 37738002)
1. Prognostic variations between 'primary' and 'progressive' muscle-invasive bladder cancer following radical cystectomy: a novel propensity score-based multicenter cohort study.
Lai S; Liu J; Lai CH; Seery S; Hu H; Wang M; Hu H; Xu T
Int J Surg; 2024 Jan; 110(1):270-279. PubMed ID: 37738002
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the prognosis of primary vs. progressive muscle invasive bladder cancer after radical cystectomy: Results from a large multicenter study.
Nouhaud FX; Chakroun M; Lenormand C; Ouzaid I; Peyronnet B; Gryn A; Prudhomme T; Grafeille V; Soulié M; Roumiguié M; Verhoest G; Xylinas E; Bouzouita A; Chebil M; Pfister C
Urol Oncol; 2021 Mar; 39(3):195.e1-195.e6. PubMed ID: 33214030
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the prognosis of primary and progressive muscle-invasive bladder cancer after radical cystectomy: A systematic review and meta-analysis.
Chen J; Zhang H; Sun G; Zhang X; Zhao J; Liu J; Shen P; Shi M; Zeng H
Int J Surg; 2018 Apr; 52():214-220. PubMed ID: 29496649
[TBL] [Abstract][Full Text] [Related]
4. Comparative survival analysis of bladder preservation therapy versus radical cystectomy in muscle-invasive bladder cancer.
Kang NW; Feng YH; Lin KL; Chen YC; Ho CH; Yang CC
Cancer Med; 2024 Jan; 13(2):e6972. PubMed ID: 38379322
[TBL] [Abstract][Full Text] [Related]
5. Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis.
Zhou YX; Hu QC; Zhu YJ; Mu XL; Liu JY; Chen Y
Eur J Med Res; 2023 Oct; 28(1):422. PubMed ID: 37822001
[TBL] [Abstract][Full Text] [Related]
6. Oncological outcome of primary versus secondary muscle-invasive bladder cancer is comparable after radical cystectomy.
Aziz A; Gierth M; Fritsche HM; May M; Otto W; Denzinger S; Wieland WF; Merseburger A; Riedmiller H; Kocot A; Burger M
Urol Int; 2013; 91(1):97-102. PubMed ID: 23751372
[TBL] [Abstract][Full Text] [Related]
7. Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy.
Moschini M; Sharma V; Dell'oglio P; Cucchiara V; Gandaglia G; Cantiello F; Zattoni F; Pellucchi F; Briganti A; Damiano R; Montorsi F; Salonia A; Colombo R
BJU Int; 2016 Apr; 117(4):604-10. PubMed ID: 25851271
[TBL] [Abstract][Full Text] [Related]
8. Risk factors and oncological outcomes of urethral recurrence in male patients with muscle invasive bladder cancer after radical cystectomy combined with urinary diversion: a propensity score-matched case control study.
Yao Z; Jiang Y; Zhu X; Wu B; Bai S
Int J Clin Oncol; 2020 Jul; 25(7):1377-1384. PubMed ID: 32318904
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and outcomes of transurethral resection versus radical cystectomy for muscle-infiltrating bladder cancer in the United States: A population-based cohort study.
Zheng Y; Ye Y; Chen J; Wei Z; Liu Z; Yu K; Zhang X
Int J Surg; 2022 Jul; 103():106693. PubMed ID: 35690361
[TBL] [Abstract][Full Text] [Related]
10. History of Non-Muscle-Invasive Bladder Cancer May Have a Worse Prognostic Impact in cT2-4aN0M0 Bladder Cancer Patients Treated With Radical Cystectomy.
Kayama E; Kikuchi E; Fukumoto K; Shirotake S; Miyazaki Y; Hakozaki K; Kaneko G; Yoshimine S; Tanaka N; Takahiro M; Kanai K; Oyama M; Nakajima Y; Hara S; Monma T; Oya M
Clin Genitourin Cancer; 2018 Oct; 16(5):e969-e976. PubMed ID: 29778322
[TBL] [Abstract][Full Text] [Related]
11. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
12. Significance of preoperative butyrylcholinesterase as an independent predictor of survival in patients with muscle-invasive bladder cancer treated with radical cystectomy.
Koie T; Ohyama C; Yamamoto H; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Kitayam M; Hirota K
Urol Oncol; 2014 Aug; 32(6):820-5. PubMed ID: 24951323
[TBL] [Abstract][Full Text] [Related]
13. Predictors of trimodality therapy in patients with muscle-invasive bladder cancer and effect on survival.
Tang Y; Lin L; Xiao Y; Meng L; Yang Y; Li X
Clin Transl Oncol; 2024 Feb; 26(2):446-455. PubMed ID: 37389736
[TBL] [Abstract][Full Text] [Related]
14. Persistent muscle-invasive bladder cancer after neoadjuvant chemotherapy: an analysis of Surveillance, Epidemiology and End Results-Medicare data.
Lane G; Risk M; Fan Y; Krishna S; Konety B
BJU Int; 2019 May; 123(5):818-825. PubMed ID: 30126053
[TBL] [Abstract][Full Text] [Related]
15. Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle-invasive bladder cancer.
Ritch CR; Balise R; Prakash NS; Alonzo D; Almengo K; Alameddine M; Venkatramani V; Punnen S; Parekh DJ; Gonzalgo ML
BJU Int; 2018 May; 121(5):745-751. PubMed ID: 29281848
[TBL] [Abstract][Full Text] [Related]
16. Intermediate-term survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non-muscle invasive bladder cancer in The Netherlands.
Hinsenveld FJ; Boormans JL; van der Poel HG; van der Schoot DKE; Vis AN; Aben KKH; Arends TJ; Ausems PJ; Baselmans D; Berger C; Berrens A; Bickerstaffe H; Bos SD; Braam M; Buddingh KT; Claus S; Dekker K; van Doeveren T; Einerhand S; Fossion L; van Gennep EJ; van Ginkel N; Palacios G; Hermans T; Hobijn MM; van Huystee SH; Jaspers-Valentijn M; Klaver OS; Koldewijn EL; Korsten L; Lenting A; Lentjes KJ; Luiting HB; van der Meer S; Nieuwenhuijzen JA; Noordzij MA; Nooter RI; Notenboom C; Oomen R; van Roermund J; de Rooij J; Roshani H; Schrier BP; van der Slot MA; Somford DM; Stelwagen PJ; Stroux A; van der West A; Wijsman BP; Windt W; van Zanten P; van Beek SC;
Urol Oncol; 2022 Feb; 40(2):60.e1-60.e9. PubMed ID: 34303597
[TBL] [Abstract][Full Text] [Related]
17. Survival after radical cystectomy: Progressive versus De novo muscle invasive bladder cancer.
Vlaming M; Kiemeney LALM; van der Heijden AG
Cancer Treat Res Commun; 2020; 25():100264. PubMed ID: 33316558
[TBL] [Abstract][Full Text] [Related]
18. The impact of orthotopic neobladder vs ileal conduit urinary diversion after cystectomy on the survival outcomes in patients with bladder cancer: A propensity score matched analysis.
Su X; Wu K; Wang S; Su W; Li C; Li B; Mao X
Cancer Med; 2020 Oct; 9(20):7590-7600. PubMed ID: 32869540
[TBL] [Abstract][Full Text] [Related]
19. Primary versus secondary muscle-invasive bladder cancer: survival after curative treatment.
Møller CT; Fosså SD; Tafjord G; Babigumira R; Berge V; Andreassen BK
Scand J Urol; 2022 Jun; 56(3):214-220. PubMed ID: 35506475
[TBL] [Abstract][Full Text] [Related]
20. HER2 overexpression predicts pathological T2 stage and improved survival in de novo muscle-invasive bladder cancer after immediate radical cystectomy: a retrospective cohort study.
Kim SW; Yu H; Kim Y; Nam KH; Chae HK; Nam W; Eom DW; Park JY; Kim SJ
Int J Surg; 2024 Feb; 110(2):847-858. PubMed ID: 37916931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
